Our Services
Medical Information
Helpful Resources
Published on: 5/21/2026
Persistent asthma often remains uncontrolled with inhaled corticosteroids alone. Breo Ellipta combines fluticasone furoate and vilanterol in a single once-daily inhaler to both reduce airway inflammation and relax bronchial muscles, improving lung function and lowering the risk of exacerbations.
There are several important factors to consider, including clinical benefits, proper inhaler technique, potential side effects, and safety precautions. See below for the complete details to guide your next steps in asthma management.
Persistent asthma is a chronic lung condition where inflammation and narrowing of the airways cause recurring symptoms like wheezing, coughing, chest tightness, and shortness of breath. For many people, inhaled corticosteroids (ICS) alone may not fully control these symptoms. That's where Breo Ellipta steps in. This once-daily inhaler combines two powerful medicines to help maintain lasting relief and improve lung function.
In this article, we'll explore:
As always, speak to a doctor about anything that could be life threatening or serious.
Breo Ellipta is a prescription inhaler containing two active ingredients:
Together, these medicines address two key aspects of persistent asthma:
By combining them in one device, Breo Ellipta offers convenience and a consistent dosing schedule.
Asthma involves chronic inflammation of the airways plus periodic tightening of the surrounding smooth muscle. Breo Ellipta targets both:
Reducing Inflammation
Relaxing Airway Muscles
Because both actions happen simultaneously, Breo Ellipta supports ongoing control of asthma symptoms and helps prevent flare-ups.
Clinical studies demonstrate multiple advantages for people whose asthma remains uncontrolled on low- or medium-dose ICS alone. Key benefits include:
These outcomes contribute to more reliable, long-term asthma management.
Several randomized controlled trials provide the evidence base for Breo Ellipta:
These findings support its role in enhancing persistent asthma control for people inadequately managed on monotherapy.
Breo Ellipta is generally prescribed for adults and adolescents (12 years and older) with:
It is not a rescue inhaler. For sudden breathing problems, you still need a fast-acting reliever (e.g., albuterol).
Proper technique and adherence are essential:
Take Breo Ellipta once every 24 hours, at the same time each day, to maintain steady medication levels.
While many people tolerate Breo Ellipta well, be aware of:
Common side effects
Less common but serious
Precautions
Always tell your doctor about all other medications and health conditions.
Medication is only one part of the picture. To optimize persistent asthma control, consider:
If you're unsure whether your symptoms are well-controlled, using a free AI-powered Bronchial Asthma symptom checker can help you gain insight into your condition and prepare meaningful questions for your next doctor's visit.
Breo Ellipta can be a cornerstone of effective, once-daily therapy for those with persistent asthma. However, every person's condition is unique. If you experience:
…seek medical attention immediately.
For ongoing care, speak to a doctor about whether Breo Ellipta fits your asthma management plan. They can tailor treatment, monitor for side effects, and adjust doses as needed.
Persistent asthma control is within reach with the right combination of medication, self-management, and professional support. Breo Ellipta's dual action on inflammation and bronchoconstriction offers reliable, once-daily relief—helping you breathe easier day after day.
(References)
* O'Byrne PM, Barnes PJ, Bleecker ER, et al. Fluticasone furoate/vilanterol and airway inflammation in asthma. Respir Res. 2016 Apr 4;17(1):37. doi: 10.1186/s12931-016-0352-0. PMID: 27040409; PMCID: PMC4820847.
* Samaan T, Taneja A, Sethi S, Salgado M. Fluticasone Furoate and Vilanterol Trifenatate as a Single Inhaler in Adolescent and Adult Patients With Asthma: A Review. J Pharm Pract. 2018 Jun;31(3):360-366. doi: 10.1177/0897190017726529. Epub 2017 Aug 25. PMID: 28848419.
* Dhillon S. Fluticasone Furoate/Vilanterol: A Review of Its Use in Asthma. Drugs. 2013 Oct;73(15):1713-25. doi: 10.1007/s40265-013-0133-7. PMID: 24057829.
* Lipworth B, Lipworth S. Once-daily fluticasone furoate/vilanterol in asthma: an update for clinicians. Expert Rev Respir Med. 2018 Mar;12(3):215-220. doi: 10.1080/17476348.2018.1428387. Epub 2017 Nov 26. PMID: 29339395.
* Khurana R, Vashisht P, Saini N, Kaur M. Fluticasone Furoate/Vilanterol for the Treatment of Asthma: An Evidence-Based Review. Clin Drug Investig. 2017 Apr;37(4):307-316. doi: 10.1007/s40261-017-0498-6. PMID: 28270764.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.